ST2, PIVKA-II, CEA, CA125 and their combinations in elderly liver metastases cancers: Development of a diagnostic scoring model

doi:10.4251/wjgo.v18.i7.118940

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 7

This Article

(19)

(18)

(0)

(1)

(265)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Jul 15, 2026; 18(7): 118940
Published online Jul 15, 2026. doi: 10.4251/wjgo.v18.i7.118940

Table 1 Comparison of clinical data between the two groups, n (%)

Variable	Construct group (n = 336)	Validation group (n = 144)	χ²/t	P value
Age (years), mean ± SD	68.03 ± 8.45	68.15 ± 8.33	0.711	0.477
Gender			0.731	0.392
Male	194 (57.74)	76 (52.78)
Female	142 (42.26)	68 (47.22)
Blood type			1.140	0.767
A	86 (25.60)	39 (27.08)
B	84 (25.00)	33 (22.92)
O	81 (24.10)	35 (24.31)
AB	85 (25.30)	37 (25.69)
Diet			1.454	0.228
Low-fat and low-cholesterol	178 (52.98)	81 (56.25)
High fat and high cholesterol	158 (47.02)	63 (43.75)
Nature of work			1.449	0.229
Brainpower	123 (36.61)	48 (33.33)
Physical strength	213 (63.39)	96 (66.67)
Course of illness (months)			0.726	0.394
< 3	170 (50.60)	77 (53.47)
≥ 6	166 (49.40)	67 (46.53)
BMI (kg/m²)			1.977	0.160
20-25	243 (72.32)	109 (75.69)
≥ 25	93 (27.68)	35 (24.31)
Installments			0.93	0.531
Phase I-II	168 (50.00)	69 (47.92)
Phase III	168 (50.00)	75 (52.08)
History of hepatitis B			2.216	0.137
Have	83 (24.70)	29 (20.14)
None	253 (75.30)	115 (79.86)
ST2 (pg/mL)	58.92 (44.36, 198.74)	62.34 (45.88, 215.47)	1.619	0.106
PIVKA-II (mAU/mL)	45.23 (24.67, 415.78)	48.15 (26.33, 398.72)	1.702	0.089
CEA (ng/mL)	8.91 (3.12, 89.45)	9.45 (3.34, 85.12)	1.720	0.086
CA125 (U/mL)	31.25 (21.08, 65.44)	32.17 (22.10, 68.95)	1.804	0.072
Fatty liver			0.651	0.420
Have	60 (17.86)	30 (20.83)
None	276 (82.14)	114 (79.17)

BMI: Body mass index; ST2: Soluble growth-stimulating gene 2; PIVKA-II: Protein induced by vitamin K absence or antagonist-II; CEA: Carcinoembryonic antigen; CA125: Carbohydrate antigen 125.

Full Size Table

Citation: Cheng Y, Sun YS, He YM. ST2, PIVKA-II, CEA, CA125 and their combinations in elderly liver metastases cancers: Development of a diagnostic scoring model. World J Gastrointest Oncol 2026; 18(7): 118940
URL: https://www.wjgnet.com/1948-5204/full/v18/i7/118940.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i7.118940

Cheng Y, Sun YS, He YM. ST2, PIVKA-II, CEA, CA125 and their combinations in elderly liver metastases cancers: Development of a diagnostic scoring model. World J Gastrointest Oncol 2026; 18(7): 118940 [DOI: 10.4251/wjgo.v18.i7.118940]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.